



## Immunologic Mechanisms of Diabetic Ulcers

Guest Editors:

### Dr. Ruchi Roy

UICentre for Drug Discovery,  
College of Pharmacy, University  
of Illinois Chicago, Chicago, IL  
60612, USA

### Dr. Sunil Singh

Department of Surgery, Division  
of Surgical Oncology, University  
of Illinois Chicago, Chicago, IL  
60612, USA

Deadline for manuscript  
submissions:

**closed (1 December 2022)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue aims to give an overview of the most recent advances in the field of therapeutic approaches to control wound infections and promote wound healing. This Special Issue is aimed at providing selected contributions on advances in the therapeutic approaches and applications of immunomodulators to treat diabetic ulcers.

Potential topics include, but are not limited to:

- Antimicrobial defenses;
- Immunomodulators strategies;
- Therapeutic approaches to control infection and promote wound healing;
- Mechanistic studies;
- Adverse effects of immunomodulators on wound healing;
- Identification of the molecular regulators;
- Identification of targets potentially useful in future clinical trials;
- Future perspectives for immunomodulators strategies.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)